WO2000002523A3 - Vaccine against staphylococcus intoxication - Google Patents

Vaccine against staphylococcus intoxication Download PDF

Info

Publication number
WO2000002523A3
WO2000002523A3 PCT/US1999/015569 US9915569W WO0002523A3 WO 2000002523 A3 WO2000002523 A3 WO 2000002523A3 US 9915569 W US9915569 W US 9915569W WO 0002523 A3 WO0002523 A3 WO 0002523A3
Authority
WO
WIPO (PCT)
Prior art keywords
intoxication
vaccine against
against staphylococcus
aureus
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015569
Other languages
French (fr)
Other versions
WO2000002523A2 (en
WO2000002523A9 (en
Inventor
John S Lee
Peter Pushko
Jonathan F Smith
Robert G Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research Institute of Infectious Diseases
Original Assignee
US Army Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research Institute of Infectious Diseases filed Critical US Army Medical Research Institute of Infectious Diseases
Priority to AT99943610T priority Critical patent/ATE443768T1/en
Priority to EP99943610A priority patent/EP1097213B1/en
Priority to DE69941454T priority patent/DE69941454D1/en
Priority to AU56673/99A priority patent/AU761021B2/en
Priority to CA002337966A priority patent/CA2337966A1/en
Publication of WO2000002523A2 publication Critical patent/WO2000002523A2/en
Publication of WO2000002523A9 publication Critical patent/WO2000002523A9/en
Publication of WO2000002523A3 publication Critical patent/WO2000002523A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Using nucleic acids encoding non-toxic mutant SEA and SEB exotoxins from Staphylococcus aureus, compositions and methods for use in inducing an immune response which is protective against staphylococcal aureus intoxication in subjects is described.
PCT/US1999/015569 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication Ceased WO2000002523A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT99943610T ATE443768T1 (en) 1998-07-10 1999-07-09 VACCINE AGAINST STAPHYLOCOCCO POISONING
EP99943610A EP1097213B1 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication
DE69941454T DE69941454D1 (en) 1998-07-10 1999-07-09 VACCINE AGAINST STAPHYLOKOKEN POISONING
AU56673/99A AU761021B2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication
CA002337966A CA2337966A1 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
US60/092,416 1998-07-10

Publications (3)

Publication Number Publication Date
WO2000002523A2 WO2000002523A2 (en) 2000-01-20
WO2000002523A9 WO2000002523A9 (en) 2000-07-27
WO2000002523A3 true WO2000002523A3 (en) 2000-11-23

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015569 Ceased WO2000002523A2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication
PCT/US1999/015568 Ceased WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015568 Ceased WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine

Country Status (7)

Country Link
US (2) US6632640B1 (en)
EP (2) EP1097213B1 (en)
AT (2) ATE443768T1 (en)
AU (2) AU761021B2 (en)
CA (2) CA2339355A1 (en)
DE (2) DE69940157D1 (en)
WO (2) WO2000002523A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1105154B1 (en) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Bacterial superantigen vaccines
EP1171194A1 (en) 1999-04-16 2002-01-16 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Drug delivery device comprising a dual chamber reservoir
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (en) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US7888490B2 (en) 2001-12-05 2011-02-15 Centre of Biotechnology Jawaharlal Nehru University Process for the preparation of non-toxic anthrax vaccine
US20040082530A1 (en) * 2002-04-11 2004-04-29 Schmaljohn Connie S. Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
KR101518309B1 (en) * 2003-03-20 2015-05-08 알파벡스, 인크. Improved alphavirus replicons and helper constructs
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
EP1651666B1 (en) * 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
WO2005026203A2 (en) 2003-09-18 2005-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna promoters and anthrax vaccines
ES2422171T3 (en) 2004-02-11 2013-09-09 Ligocyte Pharmaceuticals Inc Anthrax antigens and use procedures
EP2298340B1 (en) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
KR20080052509A (en) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 Vaccines Against Pandemic Flu Virus
EA014739B1 (en) 2005-09-09 2011-02-28 Лабофарм Инк. TRAZODON COMPOSITION FOR INTRODUCTION ONCE A DAY
RU2008113439A (en) 2005-09-09 2009-10-20 Лабофарм Инк. (CA) COMPOSITIONS WITH SLOW DELIVERY OF A MEDICINAL PRODUCT
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (en) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Methods and compositions related to immunity against staphylococcal lung disease and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
ES2655701T3 (en) 2010-07-02 2018-02-21 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (en) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Methods and compositions involving protective staphylococcal antigens
CA2830415A1 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
HRP20201127T1 (en) 2012-04-26 2020-11-27 University Of Chicago STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF APPLICATION
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2014205111A1 (en) 2013-06-19 2014-12-24 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
EA201891601A1 (en) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
US11260120B2 (en) 2017-07-27 2022-03-01 Integrated Biotherapeutic Vaccines, Inc. Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
EA202193121A1 (en) 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. CANCER TREATMENT
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
WO1996037616A1 (en) * 1995-05-23 1996-11-28 The University Of North Carolina At Chapel Hill Alphavirus rna replicon systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681341B2 (en) * 1992-01-28 1997-08-28 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
EP1055429A4 (en) * 1998-02-15 2004-09-08 Juridical Foundation NEW PREVENTIVE / CURATIVE DRUGS FOR IMMUNOPATHY
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
EP1105154B1 (en) * 1998-08-13 2016-06-01 Walter Reed Army Institute of Research Bacterial superantigen vaccines
AU771774B2 (en) * 1998-12-07 2004-04-01 U.S. Medical Research Institute Of Infectious Diseases Live attenuated Venezuelan equine encephalitis vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
WO1996037616A1 (en) * 1995-05-23 1996-11-28 The University Of North Carolina At Chapel Hill Alphavirus rna replicon systems

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
I-M. NILSSON ET AL.,: "Protection against Staphylococcus aureus sepsis by vaccination with recombinant Staphylococcal Enterotoxin A devoid of superantigenicity", J. INFECTIOUS DISEASES, vol. 180, October 1999 (1999-10-01), pages 1370 - 1373, XP002141820 *
PUSHKO P ET AL: "Replicon-helper systems from attenuated Venezuelan Equine Encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 239, no. 2, 22 December 1997 (1997-12-22), pages 389 - 401, XP002123951, ISSN: 0042-6822 *
R.G. ULRICH ET AL.,: "Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules", NATURE STRUCTURAL BIOLOGY, vol. 2, no. 6, June 1995 (1995-06-01), pages 554 - 560, XP000916120 *
S. BAVARI AND R.G. ULRICH: "Engineered bacterial superantigen vaccines", TOXICON, vol. 36, September 1998 (1998-09-01), pages 1231 - 1232, XP000916192 *
S. BAVARI ET AL.,: "Engineered bacterial superantigen vaccines", VACCINES, vol. 96, 1996, pages 135 - 141, XP000916124 *
S. BAVARI ET AL.,: "Superantigen Vaccines: a comparative study of genetically attenuated receptor-binding mutantsof Staphylococcal Enterotoxin A", J. INFECT. DISEASES, vol. 174, no. 2, August 1996 (1996-08-01), pages 338 - 345, XP000916129 *
ULRICH R G ET AL: "Development of engineered vaccines effective against structurally related bacterial superantigens", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 19, 1 November 1998 (1998-11-01), pages 1857 - 1864, XP004139018, ISSN: 0264-410X *

Also Published As

Publication number Publication date
ATE418612T1 (en) 2009-01-15
EP1097213A2 (en) 2001-05-09
EP1097212B1 (en) 2008-12-24
WO2000002522A2 (en) 2000-01-20
WO2000002523A2 (en) 2000-01-20
AU5542699A (en) 2000-02-01
CA2337966A1 (en) 2000-01-20
ATE443768T1 (en) 2009-10-15
WO2000002522A3 (en) 2000-10-12
CA2339355A1 (en) 2000-01-20
US6632640B1 (en) 2003-10-14
US7374931B2 (en) 2008-05-20
WO2000002523A9 (en) 2000-07-27
DE69940157D1 (en) 2009-02-05
US20040009183A1 (en) 2004-01-15
AU758019B2 (en) 2003-03-13
DE69941454D1 (en) 2009-11-05
AU761021B2 (en) 2003-05-29
AU5667399A (en) 2000-02-01
EP1097212A2 (en) 2001-05-09
WO2000002522A9 (en) 2001-04-05
EP1097213B1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
DE69940157D1 (en) Anthrax-impfstoff
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2005032582A3 (en) Immunogenic compositions for streptococcus pyogenes
FI970799L (en) Mutant enterotoxin, an effective non-toxic oral adjuvant
WO2000002524A3 (en) Botulinum neurotoxin vaccine
AU6867801A (en) Fusion proteins of mycobacterium tuberculosis
AU2003223497A1 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2002217903A1 (en) Universal restraint system
AU2002345653A1 (en) Diagnostic device, system and method
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
BRPI9700768B1 (en) live vaccine to fight streptococcus infection in horses.
EP2275120A3 (en) Protein-based streptococcus pneumoniae vaccines
AU1757601A (en) Cross-protective salmonella vaccines containing an avirulent salmonella choleraesuis strain
WO2000061724A3 (en) Anti-bacterial vaccine compositions
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO1999058639A3 (en) Structural proteins of fish pancreatic disease virus and uses thereof
AU2002216777A1 (en) Line guidance device
AU2001277785A1 (en) Estrous detection system
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2001077365A3 (en) Antimicrobial methods and materials
EP0875574A3 (en) Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
WO2002011549A3 (en) Treatment of mycobacterial infection
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; PAGES 1-3, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2337966

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999943610

Country of ref document: EP

Ref document number: 56673/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999943610

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 56673/99

Country of ref document: AU